Characteristics | USA100 N = 36 | USA300 N = 29 | P-value |
---|---|---|---|
Patient characteristics | |||
Gender: Female | 16 (44 %) | 9 (31 %) | 0.269 |
Age ≥55 years | 24 (67 %) | 11 (38 %) | 0.021 |
Hospital admission within previous 12 months | 21 (58 %) | 11 (38 %) | 0.102 |
Hospital-acquired infection | 10 (28 %) | 12 (41 %) | 0.249 |
Previous MRSA infection or colonization | 8 (22 %) | 5 (17 %) | 0.618 |
Positive influenza test | 1 (3 %) | 2 (7 %) | 0.582 |
Post-infection length of stay: median (IQR), in daysa | 6 (2–18) | 12 (4–24) | 0.232 |
Charlson Comorbidity Index score: median (IQR) | 2 (1–3) | 2 (0–4) | 0.778 |
30-day mortalityb | 11 (31 %) | 4 (14 %) | 0.111 |
Antimicrobial prescribed | |||
Linezolid | 11 (31 %) | 2 (7 %) | 0.018 |
Vancomycin | 33 (92 %) | 29 (100 %) | 0.247 |
Microbial characteristics | |||
agr dysfunction | 8 (22 %) | 4 (14 %) | 0.384 |
Toxic shock syndrome toxin-1 | 1 (3 %) | 0 (0 %) | 1.000 |
hVISA | 1 (3 %) | 0 (0 %) | 1.000 |
Arginine catabolic mobile element | 1 (3 %) | 23 (79 %) | <0.001 |
Panton-Valentine leukocidin | 0 (0 %) | 26 (90 %) | <0.001 |
SCCmec | |||
Type II | 35 (97 %) | 4 (14 %) | <0.001 |
Type IV | 0 (0 %) | 25 (86 %) | <0.001 |